SCM
GNCA

Stevens Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Stevens Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,564
Closed -$86K – 1254
2015
Q3 		$86K Buy
+1,564
New +$155K ﹤0.01% 908

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Stevens Capital Management's GNCA Position: Q4 2015 in Review

Stevens Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2015, closing a stake of 1,564 shares — an estimated $86K sold.

Stevens Capital Management first reported a position in GNCA in Q3 2015 and held it in 1 quarter. The position peaked at $86K in Q3 2015. 57 funds tracked by Wall St. Rank hold GNCA as of Q4 2015.

  • Stevens Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q4 2015 after selling out during the quarter.
  • Stevens Capital Management sold 1,564 Genocea Biosciences, Inc. shares in Q4 2015, an estimated $86K.
  • Stevens Capital Management first reported a position in Genocea Biosciences, Inc. in Q3 2015 and held it in 1 quarter.
  • Stevens Capital Management's Genocea Biosciences, Inc. position peaked at $86K in Q3 2015.
  • 57 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2015.

Based on Stevens Capital Management's 13F filing for Q4 2015, filed 5 Feb 2016.